24/7 Market News Snapshot 25 June, 2025 – GlucoTrack, Inc. Common Stock (NASDAQ:GCTK)

June 25, 2025

DENVER, Colo., 25 June, 2025 (www.247marketnews.com) – (NASDAQ:GCTK) are discussed in this article.
GlucoTrack, Inc. (GCTK) is witnessing significant bullish momentum, trading at $9.318 during pre-market sessions, reflecting a notable 50.05% increase from the prior day’s closing value of $6.210. This surge indicates heightened investor interest, with a trading volume of 1.84 million shares, suggesting robust activity surrounding the company. Market observers are encouraged to monitor this trend, as GCTK appears well-positioned for continued expansion.

In a landmark development, GlucoTrack recently announced the successful results of its first-in-human clinical study for the Continuous Blood Glucose Monitor (CBGM) at the American Diabetes Association’s 85th Scientific Sessions. The trial met all primary and secondary endpoints, showcasing the technology’s accuracy with a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs and an exceptional 99% data capture rate. Importantly, no serious adverse events were reported, affirming the device’s safety in a clinical setting.

This pioneering implantable device directly measures blood glucose levels, addressing the latency issues associated with traditional glucose monitors that rely on interstitial fluid. Backed by OneTwo Analytics, the study demonstrated that 92% of measurements remained within the green zone of the Diabetes Technology Society Error Grid, highlighting the efficacy of this technology.

Conducted with ten participants undergoing intensive insulin therapy, the trial confirmed consistent performance and minimal lag times during glucose tolerance tests. Following a seamless three-day inpatient monitoring period, the device’s components were removed safely, further validating its potential.

Dr. Paul V. Goode, President and CEO of GlucoTrack, emphasized the significance of this milestone, stating that it brings the company closer to offering a long-term, less intrusive solution for diabetes management. Looking ahead, GlucoTrack is set to initiate a long-term early feasibility study in Q3 2025, reinforcing its commitment to advancing patient care and enhancing quality of life for those managing diabetes.

Related news for (GCTK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.